Table 1 Baseline clinicopathological characteristics of patients with APC.
Valuables | Category | Characteristics |
|---|---|---|
Gender | Male | 92 (64.8%) |
Female | 50 (35.2%) | |
Age | Median (Range) | 61 (34–86) |
ECOG PS | 0 | 14 (9.9%) |
1 | 108 (76.1%) | |
2 | 20 (14.1%) | |
Primary tumor location | Head and neck | 61 (43.0%) |
Body and tail | 81 (57.0%) | |
TNM stage | III | 41 (28.9%) |
IV | 101 (71.1%) | |
Liver metastasis | Yes | 71 (50.0%) |
No | 71 (50.0%) | |
Chemotherapy | Gemcitabine monotherapy | 50 (35.2%) |
Gemcitabine combination therapy | 45 (31.7%) | |
Gemcitabine exclusive therapy | 47 (33.1%) | |
Albumin (g/L) | Median (Range) | 39.2 (26.1–48.4) |
CRP (mg/L) | Median (Range) | 3.55 (0.2–178.0) |
CAR | Median (Range) | 0.099 (0.004–5.266) |
GPS | 0 | 79 (55.6%) |
1 | 47 (33.1%) | |
2 | 16 (11.3%) | |
mGPS | 0 | 92 (64.8%) |
1 | 34 (23.9%) | |
2 | 16 (11.3%) | |
AST (IU/L) | Median (Range) | 25.0 (7.3–1529.0) |
ALT (IU/L) | Median (Range) | 20.9 (5.0–1300.0) |
CA19–9 (U/ml) | Median (Range) | 430.45 (0.60–2084.00) |
CEA (ng/ml) | Median (Range) | 6.57 (0.40–1065.00) |
Hemoglobin (g/L) | Median (Range) | 122 (75–168) |
